<div>
  <h1>Indication and Usage</h1>
  <p>NAVSUNLI is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of patients with mucopolysaccharidosis type II (MPS II; Hunter syndrome).</p>
  <p>This indication is approved under accelerated approval based on 4-month reductions in CSF D2S6 biomarker <a href="#pharmacodynamics" class="internal-link">(see Clinical Pharmacology)</a>. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</p>
</div>

